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ABSTRACT
The increasing number of scientific reports on the new-generation tyrosine kinase inhibitors and immunological 
checkpoint inhibitors in the management of patients with non-small-cell lung cancer (NSCLC) results in the neces-
sity of frequent guidelines updating and constant preparing of treatment algorithms by scientific societies. This 
is accompanied by the continuous search for molecular predictive factors that could allow more personalised 
treatment and increased therapeutic benefits achieved by patients. Based on current recommendations, patients 
with mutated EGFR or rearranged ALK genes in advanced NSCLC should begin their treatment with tyrosine kinase 
inhibitors. The use of these agents within first- and second-line treatment may produce significant improvement 
of prognosis in selected patients. The improvement of survival may be achieved in patients with central nervous 
system metastases, who have poor prognosis. The role of immunotherapy increases as well, but negative results 
of some trials (e.g. MYSTIC or CheckMate 026) indicate difficulties in precise defining of groups of patients with 
the highest chances of benefit from immunotherapy. In view of the results from some trials (e.g. CheckMate 017, 
KEYNOTE 021, or PACIFIC), PD-L1 expression is not an optimal biomarker for immunotherapy. Initial results of 
some studies and retrospective analyses suggest the predictive value of other genetic or molecular abnormalities 
(e.g. high mutation load in tumour genome, microsatellite instability, or repair mechanism abnormalities). Precise 
definition of new biomarkers and ensuring the availability of genetic testing appears to be mandatory before 
widespread use of immunotherapy in clinical practice. Recently published positive results of studies testing new 
targeted agents, which have high value predictive factors, will probably influence the updates of scientific socie-
ties’ guidelines and management algorithms. The aim of this review was to assess possibilities of personalised 
treatment in patients with advanced NSCLC with the use of new generation tyrosine kinase inhibitors and immune 
checkpoint inhibitors, in view of new scientific reports.
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Introduction
Lung cancer is the first cause of death due to cancer 
worldwide, as well as in Poland. In 2015, about 1.7 million 
deaths were recorded around the world [1]. Lung cancer 
is the most commonly diagnosed cancer in men, while in 
women it ranks second after breast cancer. Five-year over-
all survival rates (all histological types and stages) do not 
exceed 20% (in Poland approx. 13.5%). High mortality 
in lung cancer patients results mainly from too late diag-
nosis due to asymptomatic disease course at early stage. 
Approximately 80% of all lung cancers are non-small 
cell lung cancer (NSCLC), which is histologically clas-
sified into three types: squamous cell carcinoma (30%), 
adenocarcinoma (45%), and large-cell carcinoma (5%); 
the remaining 20% are small cell lung cancer (SCLC) [2].
The majority of patients with advanced-stage 
NSCLC receive systemic chemotherapy, whereas in pa-
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tients with abnormalities in epidermal growth factor re-
ceptor (EGFR), anaplastic lymphoma kinase (ALK), and 
ROS1 tyrosine kinase genes it is possible to use tyrosine 
kinase inhibitors. Due to rapidly occurring resistance 
to classic cytotoxic drugs, the results of chemotherapy 
are still unsatisfactory. Molecularly targeted drugs are 
more effective, but can be used only in patients with the 
aforementioned gene disorders (in Polish population 
they compromise approx. 12% of all NSCLC cases) [3]. 
The prerequisite for obtaining optimal therapeutic 
benefits in this group of patients is reliable assessment 
of status of genes being targets for targeted therapies.
The introduction of immune checkpoint inhibitors is 
promising in many cancers (including NSCLC) in clinical 
practice. These agents — monoclonal antibodies — bind 
to the programmed death receptor 1 (PD-1) or its ligand 
(PD-L1) or cytotoxic T-lymphocyte-associated protein 
4 (CTLA4). Contrary to traditional chemotherapy, the 
mechanisms of cancer immunotherapy are mainly based on:
 — strengthening the immune system in the recognition 
of cancer cells;
 — stimulation of the immune response;
 — suppression of mechanisms that inhibit the im-
mune system.
Historically, NSCLC was considered a non-im-
munogenic tumour — the opinion was partly due to 
unsuccessful attempts to modulate the immune system 
with interleukin 2, interferon or BCG (Latin Bacillus 
Calmette-Guerin) vaccine. However, as a result of better 
understanding of immune system mechanisms and the 
use of more advanced technologies, several drugs influ-
encing the immune system (ipilimumab, pembrolizumab, 
nivolumab, atezolizumab, durvalumab, avelumab) have 
been developed — these agents reduce the body’s toler-
ance to cancer and increase the anti-cancer response.
The aim of the presented study is to summarise the 
most important results of clinical trials and conference 
reports on immunotherapy of NSCLC patients and 
treatment with molecularly targeted drugs of patients 
with activating mutations, and in particular the impact of 
these therapies on progression-free survival (PFS) and 
overall survival (OS). Considering the dynamic progress 
of knowledge, the negative results of some research, 
and increasing costs of sequential treatment, there is 
an urgent need for precise selection of patients and the 
development of an optimal algorithm for therapeutic 
treatment in advanced NSCLC.
Treatment of NSCLC patients 
harbouring EGFR mutation
Patients with the diagnosis of NSCLC and activat-
ing mutations within EGFR gene represent a special 
group. The frequency of mutations in EGFR gene is 
variable; in Caucasians it is about 12%, whereas in 
the Asian population it is found in about half of the 
patients. This mutation is most frequently detected in 
patients diagnosed with adenocarcinoma [4]. Accord-
ing to the majority of guidelines, genetic diagnosis of 
patients with non-squamous NSCLC should begin with 
EGFR gene status assessment, and in the absence of 
mutations it should also include ALK gene. The degree 
of histological differentiation has no effect on molecu-
lar diagnostic indications [5]. The current standard of 
treatment of patients with advanced NSCLC with dele-
tion in exon 19 or substitution in exon 21 is the use of 
the first- or second-generation EGFR tyrosine kinase 
inhibitor (erlotinib, gefitinib, and afatinib). The prob-
ability of benefit following the use of EGFR tyrosine 
kinase inhibitors is about 50% higher in this group of 
patients as compared to standard chemotherapy. The 
main cause of resistance to treatment with EGFR 
inhibitors in the first-line setting is the appearance of 
secondary mutation T790M. The first drug registered by 
regulatory agencies in the United States and in Europe 
(Food and Drug Administration, FMA and European 
Medicine Agency, EMA, respectively), which showed 
high efficacy in case of this mutation after the failure of 
therapy with first-line EGFR inhibitors is osimertinib. 
Osimertinib is recommended by the European Soci-
ety of Medical Oncology (ESMO) and the American 
Society of Clinical Oncology (ASCO) in a dedicated 
group of patients after confirmed occurrence of T790M 
mutation [6].
Promising observations regarding the efficacy of 
osimertinib in first-line treatment were presented 
at the ESMO 2017 Congress. In the phase III study 
(FLAURA) the advantage of osimertinib was demon-
strated relative to the standard of care (erlotinib or 
gefitinib) in terms of median progression-free survival 
(PFS) — 18.9 months compared to 10.2 months, which 
corresponds to a hazard ratio (HR) of 0.46 at the 95% 
confidence interval (CI) 0.37–0.57 and p < 0.0001. The 
median duration of response was 17.2 months and 
8.5 months, respectively. The use of osimertinib in 
first-line treatment of patients with advanced NSCLC 
with mutation in EGFR gene resulted in reduced risk 
of disease progression or death by 54% compared to 
the standard use of first-generation tyrosine kinase 
inhibitors. It should be emphasised that advantage of 
osimertinib in terms of median PFS was also demon-
strated in the subgroup of patients with central nervous 
system (CNS) metastases (15.2 months vs. 9.6 months, 
HR = 0.47, 95% CI 0.30–0.74; p = 0.0009). The 
median overall survival in the FLAURA study has 
not yet been achieved [7]. In October 2017, the FDA 
approved the accelerated registration of the drug in 
first-line treatment (justification — so-called break-
through therapy) [8].
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Treatment of patients with ALK 
rearrangement-positive NSCLC
ALK gene rearrangement occurs in 3–5% of all 
NSCLC patients and most often affects younger 
non-smokers. In patients with non-squamous NSCLC 
without EGFR mutations ESMO and ASCO guidelines 
recommend the determination of ALK and ROS1 gene 
status (in particular in patients with adenocarcinoma 
or with mixed histology with predominant adeno-
matous component). In the treatment of patients with 
advanced NSCLC with ALK or ROS1 rearrangements, 
ALK tyrosine kinase inhibitor — crizotinib — used in 
the first- or second-line of treatment is currently the 
standard of care.
The effect of crizotinib in the first-line treatment of 
patients with advanced NSCLC with ALK rearrange-
ment was evaluated in the phase III study PROFILE 
1014. The study demonstrated the superiority of crizo-
tinib over standard platinum-based chemotherapy in 
terms of median PFS (10.9 months vs. 7.0 months, 
HR = 0, 45, 95% CI 0.35–0.60; p < 0.001). It should be 
noted that 84% of patients with the control arm received 
crizotinib (crossover) after the disease progression, 
which significantly influenced the results of overall sur-
vival analysis. The final results of the study published in 
2017 showed the numerical higher activity of crizotinib in 
terms of OS as compared to chemotherapy (HR = 0.76, 
95% CI 0.548–1.053; p = 0.0489 for one-sided test), but 
it did not reach the threshold of statistical significance 
[9]. The median OS was not reached in the crizotinib 
arm, but in control arm it was 47.5 months. Therefore, 
the impact of both interventions on OS was additionally 
estimated using the RPSFT (rank-preserving structural 
failure time) model, correcting the effect of transition 
of patients from control arm to treatment with crizo-
tinib. Thereby, the estimated odds ratio (OR) for OS 
was 0.346 (stratified log-rank test) and 0.353 (stratified 
Wilcoxon test).
Not all patients with ALK gene rearrangement 
achieve response to treatment with crizotinib. Addi-
tionally, patients who have responded to this treatment 
acquire resistance after some time. If disease progresses 
during treatment with crizotinib, ESMO recommends 
the determination of ALK gene status on repeated bi-
opsy and the use of second-generation ALK inhibitors 
(alectinib or ceritinib), which are characterised by higher 
affinity and stronger tyrosine kinase inhibition, as well 
as better penetration into (CNS). For alectinib this is 
confirmed by the results of the ALUR study, in which 
the value of this drug relative to standard chemotherapy 
(pemetrexed or docetaxel) was evaluated in patients 
previously receiving crizotinib or platinum-based 
chemotherapy [10]. Preliminary results of this study, 
presented during the ESMO 2017 Congress, indicate 
a significant advantage of alectinib against control 
intervention in terms of median investigator-assessed 
PFS (9.6 vs. 1.4 months, HR = 0.15, 95% CI 0.08–0.29; 
p < 0.001) and in an independent committee review 
(7.1 vs. 1.6 months, HR = 0.32, 95% CI 0.17–0.59; 
p < 0.001). It should also be noted that alectinib has 
a significant advantage compared to standard chemo-
therapy in patients with CNS metastases, for whom ORR 
in CNS reached 54.2% in the alectinib arm versus 0% in 
the control arm (difference 54.2%; 95% CI 0.23–0.78). 
Alectinib was also characterised by a more favourable 
safety profile and provided a better health-related qual-
ity of life (HRQoL) [11]. Grade 3 or higher adverse 
events occurred in 27.1% of patients in the alectinib arm 
and in 41.2% of patients in the control arm. 
The efficacy and safety of another second-generation 
ALK inhibitor — ceritinib — was evaluated in a phase 
III study (ASCEND-5), which demonstrated superior-
ity of this drug relative to standard chemotherapy in 
the second line of treatment in terms of median PFS 
(primary endpoint). The median PFS (ceritinib vs. pem-
etrexed vs. docetaxel) was 5.4 months vs. 2.9 months 
vs. 1.5 months, respectively [12]. Initial OS analysis at 
the data cut-off did not show significant differences 
in the median between ceritinib and chemotherapy 
(18.1 months vs. 20.1 months, HR = 1.0, 95% CI 0.67–
–1.49; p = 0.5). At the same time, severe adverse events 
have been reported more frequently in the ceritinib arm 
(43% and 32%, respectively).
In 2017, the results of a phase II clinical study 
(ALTA) were also published, comparing the efficacy and 
safety of two dosing regimens for another second-gener-
ation ALK inhibitor — brigatinib — in patients with ad-
vanced NSCLC with ALK rearrangement. The patients 
were randomly assigned to arm A (brigatinib 90 mg, 
once daily) or arm B (brigatinib 180 mg, once daily). The 
study showed the superiority of brigatinib at the higher 
dose in terms of median investigator-assessed PFS (arm 
A and B — 9.2 months vs. 12.9 months, respectively; 
HR = 0.55, 95% CI 0.35–0.86) and in independent com-
mittee review (9.2 months vs. 15.6 months). Brigatinib 
at a dose of 180 mg per day also showed an advantage 
in terms of one-year survival rate (arm A and B — 71% 
vs. 80%, respectively). ORR in patients with baseline 
measurable CNS metastases in an independent commit-
tee review reached the value of 42% in arm A compared 
to 67% in arm B. Treatment-emergent adverse events 
grade 3 or higher were reported in 21% of patients in 
arm A and 26% of patients in arm B. In April 2017, the 
FDA approved the accelerated registration of the drug 
in the treatment of patients with advanced NSCLC 
with ALK rearrangement, and with disease progres-
sion after crizotinib treatment or crizotinib intolerance 
(justification — so-called breakthrough therapy) [13, 
14]. Currently, a phase III clinical study (ALTA-1L) is 
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ongoing, assessing the value of brigatinib in relation to 
crizotinib in the first line of treatment for patients with 
NSCLC with ALK rearrangement.
The current guidelines of scientific societies do 
not specify the preferred sequence of ALK inhibi-
tors use due to the lack of studies directly comparing 
alectinib to ceritinib or brigatinib in second-line treat-
ment. However, it is worth noting that in the ALEX 
study published in 2017, directly comparing alectinib 
to crizotinib in the first-line treatment of patients with 
advanced NSCLC with ALK rearrangement, an inde-
pendent committee review showed a significant ad-
vantage of alectinib over crizotinib in terms of median 
PFS (25.7 months vs. 10.4 months; HR = 0.50; 95% CI 
0.36–0.70; p < 0.001) and a rate of disease progression 
in CNS (12% vs. 45%, HR = 0.16, 95% CI 0.10–0.28; 
p < 0.0001) [15]. Based on the results of this study in 
October 2017, the Committee for Medicinal Products 
for Human Use (CHMP) issued a positive opinion 
recommending the registration of the drug in the Eu-
ropean Union in first-line treatment of patients with 
advanced NSCLC with ALK rearrangement, and the 
FDA registered the drug in this indication in November 
2017 [16, 17]. As a consequence of the aforementioned 
research results and recommendations of government 
agencies, alectinib may soon become a new standard 
of treatment for patients with advanced NSCLC with 
ALK rearrangement.
The promising preliminary results of second-phase 
trials were also obtained for other new generation in-
hibitors of ALK and ROS1 (e.g. entrectinib, lorlatinib, 
and ensartinib) [18–20]. A summary of the effect of 
ALK inhibitors on PFS and OS and frequency of grade 
3 or higher adverse events in the first- and second-line 
treatment of patients with advanced NSCLC with ALK 
rearrangement are shown in Table 1.
Monotherapy with monoclonal 
antibodies anti-PD-1 or anti-PD-L1
Pembrolizumab
In the phase I (KEYNOTE 001) and phase II/III 
studies (KEYNOTE 010), high expression of PD-L1 
(> 50% of tumour cells) has been shown to predict a bet-
ter response to pembrolizumab [21, 22]. In the phase III 
study (KEYNOTE 024), pembrolizumab was superior 
to platinum-based standard first-line chemotherapy 
in terms of median PFS (10.3 months vs. 6.0 months, 
HR = 0.50, 95% CI 0.37–0.68; p < 0.001) and ORR 
according to RECIST criteria (45.5% vs. 29.8%) as well 
as median OS (30.0 months vs. 14.2 months, HR = 0.63; 
95% CI 0.47–0.86; p = 0.002) [23–25]. The mentioned 
benefits concerned NSCLC patients with high PD-L1 ex-
pression. It should be emphasised that an advantage 
of pembrolizumab in terms of OS was demonstrated 
despite the approved crossover of 62.3% of patients 
in the control arm undergoing chemotherapy, who 
had progression of the disease, to the pembrolizumab 
arm. Pembrolizumab was also superior in terms of its 
impact on quality of life and safety profile. Grade 3 and 
4 adverse events occurred in 31.2% of patients versus 
53.3% in the control arm [23]. Currently, a phase III 
trial (KEYNOTE 042) is being conducted in which 
pembrolizumab is compared to standard chemotherapy 
in the first line of treatment for NSCLC patients with 
PD-L1 expression at the level of ≥ 1%.
Nivolumab
Nivolumab is a human IgG4 monoclonal antibody 
that binds to the PD-1 antigen. The drug was registered 
by the FDA and EMA for the treatment of patients with 
advanced NSCLC (regardless of PD-L1 expression) 
after the failure of standard platinum-based chemo-
therapy [25, 26].
The first multicentre studies evaluated the efficacy of 
nivolumab in patients with advanced squamous NSCLC 
(CheckMate 017) and advanced non-squamous NDRP 
(CheckMate 057) in a second-line setting. In a phase 
III study (CheckMate 017) involving 272 patients with 
advanced squamous NSCLC, who had previously re-
ceived platinum-based chemotherapy, nivolumab and 
docetaxel were compared [27]. The study showed higher 
efficacy of nivolumab in the primary endpoint of OS 
(9.2 months vs. 6.0 months, HR = 0.59, 95% CI 0.44– 
–0.79; p < 0.001). Benefits also included one-year sur-
vival rate (42% vs. 24%, HR = 0.59, 95% CI 0.44–0.79) 
and ORR (20% vs. 9%). However, progression-free 
survival did not favour nivolumab over docetaxel (me-
dian PFS — 3.5 months vs. 2.8 months, HR = 0.62, 
95% CI 0.47–0.81; p < 0.001). Importantly, the higher 
expression of PD-L1 was not associated with greater 
clinical benefits of nivolumab in patients with squamous 
NSCLC. Treatment-emergent adverse events grade 3 or 
4 were less frequent in patients receiving nivolumab (7% 
vs. 54%). The latest results of this study, presented at 
the ESMO 2017 Congress confirmed the higher survival 
benefits obtained by nivolumab-treated patients as com-
pared to patients in the control arm (three-year survival 
rate — 16% vs. 6%, respectively) [28].
The efficacy of nivolumab against docetaxel in 
second-line treatment of patients with advanced 
non-squamous NSCLC was assessed in a phase III study 
(CheckMate 057), in which 582 patients participated 
[29, 30]. The study included patients who previously 
underwent standard platinum-based chemotherapy. 
Some patients with the presence of mutations in the 
EGFR gene or ALK rearrangements had also previ-
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Table 1. Effect of ALK inhibitors on PFS and OS and frequency of grade 3 or higher adverse events in the first- and 
second-line treatment of patients with advanced NSCLC with ALK rearrangement 
ALK 
inhibitor 
Effect on PFS as compared to 
control intervention
Effect on OS as compared to 
control intervention
Frequency  
of grade 3  
or higher 
adverse  
events as  



















Crizotinib 10.9 vs. 7.0  
(crizotinib vs. standard 
chemotherapy) 
0.45 (95% CI 
0.35–0.60; 
p < 0.001)
Not reached  
vs. 47.5  
(crizotinib vs.  
standard  
chemotherapy) 
0.76 (95% CI 
0.548–1.053; 
p = 0.0489  
for one-side  
test)
Data not  
available
PROFILE 1014 
(phase III  
study)
Ceritinib 16.6 vs. 8.1  
(ceritinib vs.  
standard 
chemotherapy) 
0.55 (95% CI 
0.42–0.73; 
p < 0.00001)
Not reached vs. 26.2  
(ceritinib vs. standard 
chemotherapy) 
0.73 (95% CI 
0.50–1.08; 
p = 0.056)
78% vs. 62%  




(phase III  
study)
Alectinib 25.7 vs. 10.4  
(alectinib vs. crizotinib) 
IRC assessment
0.50 (95% CI 
0.36–0.70; 
p < 0.001)
Data not available 41% vs. 50%  
(alectinib vs.  
crizotinib)
ALEX  

































Alectinib 7.1 vs. 1.6  




0.32 (95% CI 
0.17–0.59; 
p < 0.001)
Data not available 27.1% vs. 41.2% 




(phase III  
study)
Ceritinib 5.4 vs. 1.6 (ceritinib  
vs. standard  
chemotherapy) 
IRC assessment
0.49 (95% CI 
0.36–0.67; 
p < 0.0001)
18.1 vs. 20.1  
(ceritinib vs.  
standard  
chemotherapy) 
1.0 (95% CI 
0.67–1.49; 
p = 0.50) 
43% vs. 32%* 




(phase III  
study)
Brigatinib 9.2 vs. 12.9  
(brigatinib 90 mg q.d. 
vs. brigatinib  
180 mg q.d.) 
Investigators 
assessment
0.55 (95% CI 
0.35–0.86)
Data not available 21% vs. 26%  
(brigatinib 
90 mg q.d. 
vs. brigatinib  
180 mg q.d.) 
ALTA  
(phase II  
study)
9.2 vs. 15.6  
(brigatinib 90 mg q.d. 
vs. brigatinib  




*Serious adverse events. IRC — Independent Review Committee; q.d. — once daily
ously received EGFR or ALK inhibitors. The study 
showed the superiority of nivolumab in the primary 
endpoint of OS (12.2 months vs. 9.4 months, HR = 0.73, 
96% CI 0.59–0.89; p = 0.002) and other efficacy para-
meters including: one-year survival rate (51% vs. 39%), 
18-month survival rate (39% vs. 23%, HR = 0.72, 95% 
CI 0.60–0.88), ORR (19% vs. 12%), and median dura-
tion of response (17 vs. 6 months). The study showed 
a positive correlation of the effect of nivolumab on the 
survival in patients with PD-L1 expression — the higher 
the PD-L1 expression, the higher the survival benefits 
obtained by patients (Table 2). Among patients without 
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PD-L1 expression, the survival in the nivolumab and 
docetaxel arms were similar.
The subgroup analysis results suggest superior-
ity of nivolumab regarding improvement of survival 
in previously smokers (n = 458, HR = 0.7, 95% CI 
0.56–0.86) with no advantage in never smokers (n = 118, 
HR = 1.02, 95% CI 0.64–1.61). Treatment-related 
grade 3 or 4 adverse events occurred less frequently 
in the nivolumab arm (10% vs. 54%). The long-term 
observation results presented at ESMO 2017 Congress 
confirmed consistent advantage of nivolumab over doc-
etaxel in terms of overall survival (three-year survival 
rate — 18% vs. 9%, respectively) [28]. 
The value of nivolumab and standard chemotherapy 
in the first-line treatment was compared in a phase III 
clinical study (CheckMate 026). The study involved 
423 patients with advanced NSCLC with PD-L1 ex-
pression > 5% [31]. Nivolumab was less effective than 
standard chemotherapy in the primary endpoint of 
PFS (4.2 months vs. 5.9 months, HR = 1.15, 95% CI 
0.91–1.45; p = 0.251) and ORR (26.1% vs. 33.5%). 
The median OS was similar in both arms (14.4 months 
vs. 13.2 months, HR = 1.02, 95% CI 0.80–1.30). Grade 
3 or 4 adverse events were less common in the experi-
mental arm (17.6% vs. 50.6%). In 60% of patients in 
the control arm nivolumab was used after disease pro-
gression (crossover). The results of the study caused 
numerous discussions in the clinical environment 
regarding the optimal place of immunotherapy in the 
treatment of NSCLC patients and the actual causes 
of significant differences as compared to KEYNOTE 
024 study. Although these differences may be partially 
explained by imbalanced characteristics of the studied 
populations (e.g. prior use of radiotherapy, differences 
in biomarker assessment, differences in the cut-off value 
for PD-L1 expression), it is generally considered neces-
sary to define more precise predictive factors, that will 
allow more optimal selection of patients with a higher 
probability of obtaining benefits from anti-PD1 treat-
ment. A retrospective exploratory subgroup analysis 
from the CheckMate 026 trial published in 2017 suggests 
that a high tumour mutational burden (TMB) may be 
a more reliable biomarker than PD-L1, or they should 
be used together [32]. According to the results of this 
Table 2. Hazard ration (HR) values for the improvement of overall survival (OS) in patients with advanced non-
squamous NSCLC in the nivolumab arm versus the docetaxel arm, depending on level of PD-L1 expression (CheckMate 
057 study) [29] 
Patients group Hazard ratio (95% CI) P value
PD-L1 expression < 1% 0.9 (0.66–1.24) 0.06
PD-L1 expression ≥ 1% 0.59 (0.43–0.82)
PD-L1 expression ≥ 5% 0.43 (0.30–0.63) 0.0004
PD-L1 expression ≥ 10% 0.4 (0.26–0.59) 0.0002
analysis, patients with TMV ≥ 243 somatic mutations 
treated with nivolumab showed a trend towards im-
provement of PFS (HR = 0.62, 95% CI 0.38–1.00) and 
improvement of ORR (46.8% vs. 28.3%) as compared 
to the intervention in the control group.
The aim of another — currently conducted — phase 
III study (CheckMate 227) is to determine the most 
beneficial first-line treatment regimen for patients with 
NSCLC with use of nivolumab (monotherapy, combina-
tion with ipilimumab or chemotherapy).
Atezolizumab
Promising results of the studies on pembrolizumab 
and nivolumab justified attempts to determine the 
value of subsequent antibodies oriented on immune 
checkpoints. An example is atezolizumab, belonging 
to IgG1 class antibodies, registered by the FDA and 
EMA in the second-line treatment of patients with 
advanced NSCLC. Unlike nivolumab and pembroli-
zumab, which bind the PD-1 receptor on the surface of 
lymphocytes, atezolizumab targets PD-L1 ligand on the 
surface of tumour cells. Its efficacy against docetaxel 
was evaluated in second-line treatment in 1225 patients 
with advanced NSCLC in the phase III trial — OAK 
[33]. Analysis of results in the intent-to-treat (ITT) 
population showed the advantage of atezolizumab 
over docetaxel in terms of impact on primary endpoint, 
which was OS (13.8 months vs. 9.6 months; HR = 0.73; 
95% CI 0.62–0.87; p = 0.0003) and median duration of 
response (16.3 months vs. 6.2 months, HR = 0.34, 95% 
CI 0.21–0.55; p < 0.0001), regardless of the histological 
type of NSCLC. The magnitude of advantage of atezoli-
zumab over docetaxel was higher in the population of 
patients with PD-L1 expression ≥ 1% in tumour cells 
(TC) and infiltrating cells (IC), where the median OS 
was 15.7 months vs. 10.3 months in the atezolizumab 
and docetaxel arms, respectively (HR = 0.74, 95% CI 
0.58–0.93; p = 0.0102). The greatest benefits of treat-
ment with atezolizumab in terms of OS were observed 
in subgroup of patients with high PD-L1 expression 
(TC ≥ 50% and IC ≥ 10%) because the median OS was 
20.5 months vs. 8.9 months, respectively (HR = 0.41, 
95% CI 0.27–0.64; p < 0.0001). The median PFS and 
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ORR were similar in both arms and accounted for 
2.8 months vs. 4.0 months, respectively (HR = 0.95, 
95% CI 0.82–1.1; p = 0.49) and 14% vs. 13%. In pa-
tients receiving docetaxel, longer OS were noticed in the 
subgroup of patients with EGFR mutation (10.5 months 
vs. 16.2 months, HR = 1.24, 95% CI 0.71–2.18), which in-
dicates lower benefits of immunotherapy. Atezolizumab 
was characterised by a more favourable safety profile.
The efficacy of atezolizumab in first-line treatment 
of patients with advanced NSCLC with PDH-L1 expres-
sion was assessed in the phase II study (BIRCH7) [34]. 
The study showed ORR of 25% and median PFS and OS 
of 7.3 months and 23.5 months, respectively. Grade 3 or 
higher adverse events occurred in 33% of patients. Di-
rect comparison of atezolizumab to standard chemo-
therapy in the first-line treatment of NSCLC patients 
with PD-L1 expression ≥ 1% is currently carried out as 
part of the phase III IMpower 110 (NCT02409342) and 
IMpower 111 (NCT02409355) studies.
Durvalumab
Another promising antibody directed selec-
tively against PD-L1 is durvalumab, which belongs to 
IgG1 class. In the phase I/II clinical study with use 
of durvalumab in the first-line treatment in patients 
with advanced NSCLC, an ORR of 28.6% (95% CI 
16.6–43.3) and a disease control rate (disease stabilisa-
tion ≥ 24 weeks) of 42.9% (95% CI 28.8–57.8) were 
achieved [35]. Median PFS was 4.0 months (95% CI 
2.3–9.1) while the median OS reached 21.0 months (95% 
CI 14.5–upper limit of the interval was not reached), and 
72% of patients were still alive after 12 months (95% CI 
56–83). There was no relationship between response rate 
and the histological type of the tumour. An open-label 
phase III clinical study (PEARL) is currently recruiting 
to assess the efficacy of durvalumab compared to stand-
ard chemotherapy in first-line treatment for NSCLC 
patients without EGFR mutations or ALK rearrange-
ments with high PD-L1 expression (≥ 25%) [36].
In 2017, preliminary results of the phase III PA-
CIFIC study were published — the study compared 
durvalumab with placebo in the consolidation treatment 
of patients with locally advanced NSCLC ineligible 
for resection the lung parenchyma and receiving plat-
inum-based chemoradiotherapy (mostly concurrent). In 
this study durvalumab showed a significant advantage 
over the comparator in terms of ORR (28.4% vs. 16.0%; 
p < 0.001), median PFS (16.8 months vs. 5.6 months, 
HR = 0.52, 95% CI 0.42–0.65; p < 0.001) and me-
dian time to death or distant metastases (23.2 months 
vs. 14.6 months, 95% CI 10.6–18.6, HR = 0.52, 95% CI 
0.39–0.69; p < 0.001) [37]. A significant advantage of 
durvalumab in terms of PFS was noticed regardless of 
the expression of PD-L1, with the criterion of positive 
expression at the level of 25% or greater (vs. lower per-
centage). Grade 3 or higher adverse events occurred in 
a similar percentage in both arms of the study (29.9% 
vs. 26.1%, respectively). Particularly important is the 
fact that in the group of patients receiving durvalumab 
radiation-induced pneumonia was not significantly more 
frequent. Results regarding effects on OS are not yet 
available, but the clinical benefit of durvalumab for the 
other endpoints assessed in the PACIFIC study suggests 
that in the near future durvalumab may be a valuable 
consolidation therapy in patients with locally advanced 
NSCLC after concomitant chemoradiation.
Avelumab
Another human anti-PD-L1 antibody tested for clini-
cal use in treatment of NSCLC patients is avelumab. In 
a multi-cohort, phase I clinical study (JAVELIN SOLID 
TUMOURS), evaluating the efficacy of avelumab in the 
first-line treatment in 156 NSCLC patients with normal 
EGFR and ALK genes, ORR was 22.4%, and the me-
dian PFS reached 17.6 weeks (an objection to the study 
is the fact that PD-L1 expression is not verified) [38]. 
Treatment-emergent grade 3 adverse events occurred in 
11% of patients. Currently, phase III clinical trials are 
underway in which avelumab is compared with stand-
ard first-line chemotherapy for patients with advanced 
NSCLC and with PD-L1 expression (JAVELIN Lung 
100) and with docetaxel in the second-line treatment 
(JAVELIN Lung 200).
Anti-PD-1/anti-PD-L1 monoclonal 
antibodies combined with 
chemotherapy
Positive results of clinical trials with use of immune 
checkpoint inhibitors in monotherapy were a justifica-
tion for attempts to determine the value of combination 
immunotherapy with chemotherapy. Preliminary results 
suggest that the combination of both treatments may 
offer greater clinical benefit to the patients.
The efficacy of combined treatment (pembroli-
zumab + pemetrexed + carboplatin) was compared with 
chemotherapy alone in first-line setting in patients with 
advanced non-squamous NSCLC in the phase I/II study 
(KEYNOTE 021, cohort G). The results presented at 
the ESMO 2017 Congress indicate that immunochemo-
therapy was superior to control intervention in terms of 
ORR (57% vs. 32%, 95% CI 7–41; p = 0.0029), median 
PFS (19.0 vs. 8.9 months, HR = 0.54, 95% CI 0.33–0.88; 
p = 0.0067), and 18-month survival rate (70% vs. 56%). 
The best results were achieved in patients with very 
high PD-L1 expression (50% or more); the responses 
in this group were more than twice as frequent after 
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immunochemotherapy (80% vs. 35%). It should be 
emphasised that 75% of patients in the control group 
received anti-PD-1/anti-PD-L1 treatment (including 
pembrolizumab) after disease progression. Data on 
median OS at the cut-off date could not be assessed 
due to insufficient long-term observation (median OS 
— not reachable vs. 20.9 months, HR = 0.59, 95% CI 
0.34–1.05; p = 0.0344). Treatment-emergent adverse 
events grade 3 or higher were more common in patients 
receiving immunochemotherapy (41% vs. 29%) [39]. 
Currently, phase III clinical trials are ongoing (KEY-
NOTE 189, KEYNOTE 407), the aim of which is to 
further verify the efficacy of pembrolizumab combined 
with chemotherapy. The results of the study may help to 
explain the relationship between the degree of PD-L1 
expression and the efficacy of combination therapy. 
Phase III studies are also underway to verify the value 
of atezolizumab combined with chemotherapy in the 
first-line treatment in NSCLC patients (IMpower 132, 
IMpower 130, IMpower 131, and IMpower 150).
Anti-PD-1/anti-PD-L1 monoclonal 
antibodies combined with 
CTL4 antibodies
Previous studies have not demonstrated the effect of 
ipilimumab combined with chemotherapy on OS in the 
first-line treatment in patients with NSCLC; however, 
attempts have been made to evaluate the effectiveness 
of the regimen involving so-called “double-block” of 
immune checkpoints (combined use of anti-PD-1/PD-L1 
antibodies with ipilimumab) [40]. Clinical studies 
evaluating the combination of pembrolizumab with ip-
ilimumab in the second-line treatment of patients with 
advanced NSCLC were started with the phase I/II clini-
cal study (KEYNOTE 021, cohorts D and H). According 
to data presented at the ASCO 2016 Congress, patients 
receiving pembrolizumab combined with ipilimumab 
achieved median PFS and OS of 6 and 17 months, 
respectively. The results of the study indicate that use 
of pembrolizumab and ipilimumab is associated with 
increased toxicity and is no more effective in terms of 
ORR than monotherapy with pembrolizumab. No cor-
relation was observed between PD-L1 expression and 
treatment outcomes [41].
The efficacy of nivolumab combined with ipilimum-
ab (two dose schedules) in the first-line treatment of 
NSCLC patients was evaluated in a phase I clinical study 
(CheckMate 012) [42]. At the data cut-off point median 
PFS was longer in patients receiving ipilimumab every 
12 weeks compared to the group with six-week dose 
intervals (8.1 months vs. 3.9 months). Two-year survival 
rates in these groups were 56% and 42% [43], respec-
tively. Higher survival benefits were noted in patients 
with PD-L1 expression ≥ 1%; however, the study was 
not sufficiently statistically powered to show differences 
in survival between the groups. The incidence of grade 
3 and 4 adverse events was similar for both ipilimumab 
regimens but significantly higher than for nivolumab 
monotherapy (CheckMate 026). It should be empha-
sised that the progression of the disease in patients 
receiving ipilimumab every six weeks occurred much 
earlier than in the group receiving drug every 12 weeks 
(the percentage of patients with progression or death 
before the first assessment in imaging tests — 44% and 
18%, respectively). The presented results may suggest 
a difference between compared groups or potentially 
unfavourable effect of early immunotherapy in some 
patients. In patients with very high PD-L1 expression 
(50% or more of cells) ORR was significantly higher in 
the case of use of “dual blockade” (92% vs. 50%) with 
a 12-month survival rate of 100%. In case of low PD-L1 
expression (< 1%), ORR after combination treatment 
did not significantly differ from the rates observed in 
other studies with nivolumab monotherapy in patients 
with NSCLC. In connection with CheckMate 026 study 
results, these data do not indicate that the patient may 
additionally benefit from use of nivolumab + ipili-
mumab regimen in the first-line treatment of NSCLC.
Phase III clinical trials are still ongoing, assessing the 
effectiveness of “dual blockade” of immune checkpoints 
(MYSTIC study — durvalumab alone or in combina-
tion with tremelimumab vs. chemotherapy; NEPTUNE 
study — durvalumab in combination with tremelimumab 
vs. chemotherapy; CheckMate 227 study — nivolumab, 
nivolumab with ipilimumab, nivolumab with chemother-
apy as compared to first-line chemotherapy alone in pa-
tients with advanced NSCLC). In July 2017, preliminary 
results of the MYSTIC study were published, indicating 
that monotherapy with durvalumab or durvalumab in 
combination with tremelimumab (CTLA-4 inhibitor) 
used in the first-line treatment of patients with advanced 
NSCLC without disorders in EGFR and ALK genes did 
not show any advantage over platinum-based chemo-
therapy [44]. According to information issued by the 
drug manufacturer, the primary endpoint (PFS) was not 
achieved in any of the experimental arms of the study. 
The study has been continued, to evaluate the effect 
of durvalumab monotherapy and a regimen contain-
ing durvalumab and tremelimumab on the secondary 
endpoint (OS).
In conclusion, the preliminary results suggest that 
for the combination of anti-PD-1/PD-L1 antibodies with 
anti-CTLA4 antibody in NSCLC patients, there was no 
clinically significant added value in terms of ORR and 
PFS. The use of these schemes was associated with the 
risk of increased toxicity. The final conclusions regard-
ing the “dual blockade” of immune checkpoints will be 
possible only after the publication of OS data and safety 
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docetaxel + nintedanib 
(adenocarcinoma, EMA), 
erlotinib (EMA)
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EGFR and ALK 
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≥ 50% Pembrolizumab Pembrolizumab Platinum derivatives
NA — not applicable
data in the longer follow-up period, which confirm the 
lack of risk to patients from potential late toxicity. 
Personalised treatment of patients with 
advanced NSCLC
Positive results of many studies on new immunother-
apy options were reflected in the update of guidelines of 
scientific societies. ESMO 2017 guidelines for the man-
agement of patients with advanced NSCLC with normal 
EGFR and ALK genes recommend the use of pembroli-
zumab in the first-line treatment in patients with good 
performance status and PD-L1 expression ≥ 50% [45]. 
ASCO 2017 guidelines recommend the use of pembroli-
zumab in this group of patients provided that PD-L1 ex-
pression is ≥ 50% [46]. Patients with low PD-L1 expres-
sion should first receive standard chemotherapy. The 
use of other immunotherapeutic methods alone or in 
combination with chemotherapy is not recommended in 
the first-line setting. The algorithm for the management 
of patients with advanced NSCLC published in August 
2017 indicates that pembrolizumab is the optimal op-
tion in patients with PD-L1 expression ≥ 50% (Table 3) 
[47]. New scientific reports on immunotherapy in 
NSCLC have been reflected in updated guidelines 
also for second-line treatment. Recommendations of 
ESMO immunotherapy for stage IV NSCLC patients 
with normal status of EGFR and ALK genes, who have 
progressed after the failure of first-line chemotherapy 
currently include nivolumab and pembrolizumab (for 
patients with PD-L1 expression > 1%) [45]. However, 
recommendations of ASCO immunotherapy of stage 
IV NSCLC patients with normal EGFR and ALK and 
ROS1 genes and with PD-L1 expression ≥ 1% in sec-
ond-line setting include monotherapy with nivolumab, 
pembrolizumab, and atezolizumab.
Therapeutic landscape
Currently, there are over 110 phase III clinical trials 
in the world assessing the effectiveness of new drugs in 
NSCLC patients, sponsored by pharmaceutical industry. 
In the near future, the results will allow the development 
of a comprehensive treatment algorithm that takes into 
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account new biomarkers [48]. Advances in the molecular 
biology of cancers and the high frequency of publications 
of new scientific reports mean that our knowledge on 
personalisation of treatment for patients with NSCLC 
is developing dynamically. In particular, we can observe 
this in the area of tyrosine kinase inhibitors and im-
munotherapy, which in some groups of patients allow 
therapeutic benefits with simultaneous reduction of tox-
icity as compared to standard chemotherapy. However, 
sequential use of new anticancer drugs and increasingly 
common administration of the studied drug to patients 
from the control arm on progression (crossover) make 
difficult the precise determination of effect of new 
drugs on OS [49]. In this context there is a growing role 
of studies based on clinical practice data. According to 
retrospective studies, the sequential use of molecularly 
targeted drugs of the new generation has led to median 
OS reaching even seven years (from the date of diag-
nosis of generalised disease) in patients with NSCLC 
with ALK rearrangement and six years in patients with 
NSCLC with EGFR mutation [50, 51]. The indicated 
values significantly exceed the recommended by ASCO 
experts the minimum values of expected increase in 
survival time, obtained due to new drugs registered for 
patients with non-squamous and squamous NSCLC [52].
Regarding immunotherapy, an example of a pro-
spective study that showed OS improvement in the 
experimental arm, despite the admission of crossover, 
is the KEYNOTE-02 study. The study also showed PFS 
improvement in the subgroup of patients with advanced 
NSCLC with high PD-L1 expression (≥ 50%) receiv-
ing pembrolizumab within the first-line treatment as 
compared to standard platinum-based chemotherapy. 
Currently, pembrolizumab remains the sole inhibitor of 
immune checkpoints registered for the first-line treat-
ment of NSCLC patients. Another promising example 
is the positive results of the PACIFIC study, suggesting 
that in the near future durvalumab may be an effective 
consolidation therapy after chemoradiation of patients 
with NSCLC at the local stage.
However, the collation of preliminary results of 
MYSTIC study with the negative results of CheckMate 
026 study suggests that the use of immune checkpoint 
inhibitors does not always offer patients a clinically 
significant therapeutic benefit. It could result from 
difficulty in precisely defining the group of patients 
that benefit the most from treatment. In this context, 
the recent FDA accelerated approval of pembroli-
zumab combined with platinum-based chemotherapy in 
NSCLC patients without PD-L1 expression appears to 
be debatable. Considering that the results of two of the 
three large studies assessing the use of immunotherapy 
in the first-line treatment of patients with advanced 
NSCLC are negative, until full data from clinical trials 
have been published, the definition of a group of patients 
with advanced NSCLC who should be qualified for im-
munotherapy may raise doubts related to ambiguous 
research results. 
The results of several clinical trials (e.g. CheckMate 
017, KEYNOTE 021, PACIFIC) indicate that PD-L1 
is not an optimal biomarker for immunotherapy. Dif-
ferences in expression of PD-L1 in various parts of 
the tumour, in primary lesions and metastases, and 
variability over time cause doubts about the predictive 
value of PD-L1 for treatment with PD1/PD-L1 in-
hibitors in patients with NSCLC. Additionally, data 
indicating the lack of advantage of immunotherapy 
over docetaxel in second-line treatment in the group of 
patients with non-squamous NSCLC, who have never 
smoked (CheckMate 057), require further verification 
in subsequent studies. It is also necessary to confirm 
the value of all combination regimens, which due to the 
potential risk of late toxicity (including those different 
than in the case of monotherapy) require confirmation 
of the safety profile in a longer period of observation.
The tests currently used to evaluate PD-L1 expres-
sion are not equivalent to each other, which is an addi-
tional constraint in the formulation of conclusions. The 
threshold value determining the expression of PD-L1 
may vary depending on the use of checkpoint inhibitors 
in monotherapy or in combination with other drugs.
The results of in-depth retrospective analysis of 
the CheckMate 026 study suggest that the predictive 
value may also have a high tumour mutational burden 
(TMB) value, and the simultaneous determination of 
PD-L1 expression and TMB may allow more precise 
selection of patients for treatment. Hence, further stud-
ies of the predictive value of microsatellite instability, 
TMB, mismatch repair deficiency, and the possibilities 
of practical use of the immune signature are being 
carried out [53–55]. The definition of new biomarkers 
seems necessary before the widespread use of immune 
checkpoint inhibitors in clinical practice.
Due to the key role of biomarkers in optimising the 
treatment of patients with NSCLC, further dynamic 
development and implementation of new diagnostic 
techniques should be predicted. An example is so-called 
“liquid biopsy”, which involves the analysis of circulat-
ing free DNA (cfDNA). The advantage of these tests 
is reduced invasiveness and the possibility of frequent 
repetition to monitor the presence of new mutations 
occurring during treatment. The new possibilities will 
also make wider access to the digital polymerase chain 
reaction (PCR) and next-generation sequencing testing, 
which are currently more expensive, but offer much 
higher sensitivity than the commonly used real-time 
PCR. This translates into greater precision in qualifying 
patients for costly treatment methods.
The key role of biomarkers in the selection of pa-
tients for treatment is also starting to be noticed by the 
33
Rafał Zyśk, Maciej Krzakowski, Personalised treatment of non-small-cell lung cancer patients
regulatory agencies responsible for drug registration. In 
2016 the FDA approved a first modern test for the de-
termination of EGFR mutations from peripheral blood 
for clinical practice (EGFR Mutation Test v2 Cobas) 
[56]. In May 2017, for the first time in history, a me-
dicinal product (pembrolizumab) was registered for the 
treatment of patients with unresectable or metastatic, 
microsatellite instability-high (MSI-H) or mismatch 
repair deficient (dMMR) solid tumours, irrespective 
of tumour location and histological type. This decision 
marks a new direction in the US agency’s approach to 
defining registration indications that can contribute to 
improving the availability of patients to modern molecu-
larly targeted treatment. The adoption of an analogical 
approach in Europe by the EMA and its approval by the 
Agency for the Assessment of Medical Technology and 
Tariffs (AOTMiT) will have a decisive impact on the 
possibility of using modern anti-cancer drugs in Poland 
under programs that would not be limited by the location 
of cancer. With growing pressure from governmental 
health technology assessment agencies to more precisely 
define the population of patients eligible for treatment 
in reimbursement systems in most European countries, 
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